Search

Displaying results 2221 - 2230 of 8469 in total
  1. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib]. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

  2. Drug

    Butenafine

    go.drugbank.com/drugs/DB01091
    Approved

    Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. In particular, butenafine acts to inhibit the activity of the squalene epo...

  3. Drug

    Phenylpropanolamine

    go.drugbank.com/drugs/DB00397
    ApprovedVet approvedWithdrawn

    It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. … Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor.

  4. Drug

    Lyme disease vaccine (recombinant OspA)

    go.drugbank.com/drugs/DB00045
    ApprovedWithdrawn

    It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

  5. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

  6. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095] … This type of virus is vastly used as vectors for gene therapy because they can infect dividing and quiescent cell integrating just the carried genes into the host genome without fully integrating into

  7. Drug

    Gadobenic acid

    go.drugbank.com/drugs/DB00743
    ApprovedInvestigational

    [A1139] Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance.[A263166] … [A263166] As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the biliary system, it is a useful contrast agent for liver MRI.

  8. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing … Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label].

  9. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  10. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … Florquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer.